Crawford Investment Counsel’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$193M Sell
886,415
-7,161
-0.8% -$1.59M 3.29% 1
2025
Q4
$204M Sell
893,576
-17,123
-2% -$3.9M 3.4% 2
2025
Q3
$211M Buy
910,699
+7,906
+0.9% +$1.61M 3.49% 2
2025
Q2
$168M Sell
902,793
-25,250
-3% -$4.69M 2.93% 2
2025
Q1
$194M Sell
928,043
-31,767
-3% -$6.18M 3.45% 1
2024
Q4
$171M Buy
959,810
+9,032
+0.9% +$1.66M 3.07% 2
2024
Q3
$188M Sell
950,778
-14,062
-1% -$2.62M 3.21% 2
2024
Q2
$165M Buy
964,840
+8,808
+0.9% +$1.46M 3.15% 2
2024
Q1
$174M Sell
956,032
-30,915
-3% -$5.33M 3.24% 2
2023
Q4
$153M Sell
986,947
-14,318
-1% -$2.09M 3.07% 2
2023
Q3
$149M Buy
1,001,265
+7,693
+0.8% +$1.13M 3.24% 2
2023
Q2
$134M Buy
993,572
+10,905
+1% +$1.6M 2.72% 2
2023
Q1
$157M Sell
982,667
-32,030
-3% -$4.9M 3.34% 2
2022
Q4
$164M Sell
1,014,697
-21,227
-2% -$3.25M 3.53% 1
2022
Q3
$139M Sell
1,035,924
-4,775
-0.5% -$685K 3.29% 1
2022
Q2
$159M Sell
1,040,699
-131,360
-11% -$20.1M 3.52% 1
2022
Q1
$190M Sell
1,172,059
-51,404
-4% -$7.47M 3.68% 1
2021
Q4
$166M Sell
1,223,463
-2,783
-0.2% -$329K 3.15% 2
2021
Q3
$132M Buy
1,226,246
+17,797
+1% +$2.03M 2.7% 3
2021
Q2
$136M Buy
1,208,449
+87,391
+8% +$9.84M 2.75% 3
2021
Q1
$121M Buy
1,121,058
+59,078
+6% +$6.32M 2.74% 3
2020
Q4
$114M Buy
1,061,980
+20,863
+2% +$2M 2.81% 2
2020
Q3
$91.2M Sell
1,041,117
-8,927
-0.9% -$840K 2.49% 7
2020
Q2
$103M Sell
1,050,044
-32,013
-3% -$2.82M 2.96% 3
2020
Q1
$82.4M Buy
1,082,057
+75,830
+8% +$6.46M 2.77% 4
2019
Q4
$89.1M Buy
1,006,227
+51,209
+5% +$4.25M 2.3% 7
2019
Q3
$72.3M Buy
955,018
+926,607
+3,261% +$63.5M 2.01% 14
2019
Q2
$2.07M Buy
28,411
+155
+0.5% +$12.2K 0.06% 150
2019
Q1
$2.28M Buy
28,256
+563
+2% +$46.1K 0.07% 149
2018
Q4
$2.55M Buy
27,693
+3,100
+13% +$273K 0.09% 123
2018
Q3
$2.33M Sell
24,593
-150
-0.6% -$14.2K 0.07% 139
2018
Q2
$2.29M Buy
24,743
+894
+4% +$87.3K 0.07% 134
2018
Q1
$2.26M Buy
23,849
+192
+0.8% +$21.1K 0.07% 129
2017
Q4
$2.29M Buy
23,657
+1,178
+5% +$111K 0.07% 128
2017
Q3
$2M Buy
22,479
+585
+3% +$44.5K 0.06% 129
2017
Q2
$1.59M Sell
21,894
-460
-2% -$30.9K 0.05% 136
2017
Q1
$1.46M Buy
22,354
+1,039
+5% +$65.3K 0.05% 141
2016
Q4
$1.33M Buy
21,315
+81
+0.4% +$4.94K 0.05% 150
2016
Q3
$1.34M Sell
21,234
-3,147
-13% -$204K 0.05% 150
2016
Q2
$1.51M Sell
24,381
-70
-0.3% -$4.26K 0.06% 131
2016
Q1
$1.4M Sell
24,451
-3,646
-13% -$203K 0.06% 129
2015
Q4
$1.66M Sell
28,097
-676
-2% -$38.9K 0.07% 111
2015
Q3
$1.57M Buy
28,773
+2,739
+11% +$178K 0.07% 118
2015
Q2
$1.75M Sell
26,034
-3,131
-11% -$204K 0.07% 115
2015
Q1
$1.71M Sell
29,165
-653
-2% -$39.4K 0.06% 117
2014
Q4
$1.95M Hold
29,818
0.07% 100
2014
Q3
$1.72M Sell
29,818
-3,432
-10% -$191K 0.06% 96
2014
Q2
$1.88M Hold
33,250
0.07% 87
2014
Q1
$1.71M Sell
33,250
-7,650
-19% -$387K 0.06% 88
2013
Q4
$2.16M Buy
40,900
+2,725
+7% +$134K 0.08% 81
2013
Q3
$1.71M Buy
38,175
+214
+0.6% +$9.49K 0.07% 86
2013
Q2
$1.57M Buy
+37,961
New +$1.66M 0.06% 87

Other funds holding ABBV

Crawford Investment Counsel's ABBV Position: Q1 2026 in Review

Crawford Investment Counsel reduced its AbbVie (ABBV) stake by 0.8% in Q1 2026, selling an estimated $1.59M and leaving 886,415 shares worth $193M. The position accounts for 3.29% of the portfolio, ranked #1.

Crawford Investment Counsel first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $211M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Crawford Investment Counsel held 886,415 shares of AbbVie worth $193M as of Q1 2026.
  • Crawford Investment Counsel sold 7,161 AbbVie shares in Q1 2026, an estimated $1.59M.
  • AbbVie made up 3.29% of Crawford Investment Counsel's portfolio in Q1 2026, its #1 holding.
  • Crawford Investment Counsel first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Crawford Investment Counsel's AbbVie position peaked at $211M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Crawford Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.